Difficult-to-treat & early PsA at #EULAR2025 GRAPPA definitions: D2T-PsA (≥3 therapies incl ≥2 b/tsDMARDs with persistent inflammation); C2M-PsA (broader: comorbidities, pain, intolerance). 95% GRAPPA consensus. Abstact OP0175 @RheumNow #EULAR2025 https://t.co/eqKmMPh80x